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Approximately 80% of prostate cancers exhibit some degree of bone metastasis. The role of the bone
marrow and the hematopoietic stem cell (HSC) niche in attracting metastatic cells and maintaining
dormancy of disseminated tumor cells (DTCs) is an increasingly important topic towards the develop-
ment of novel prostate cancer therapies. This paper reviews aspects of the HSC niche that lead to prostate
cancer cell homing and dormancy in the bone marrow. This review also discusses the role of DTCs in the
niche environment and discusses the role of erythropoietin in targeting DTCs within the HSC niche.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer cells disseminate from a primary tumor and enter the
circulation, of which less than 0.01% survive and produce metas-
tases [1]. Hematogenous circulation and lymphatic routes appear
to be major routes through which disseminating tumor cells
(DTCs) navigate. There are many challenges that tumor cells must
overcome during the metastatic process including dissociation
from neighboring cells of the primary tumor, extravasation, sur-
vival, and establishment in distant sites. DTCs have a number of
different fates including death, dormancy, or proliferation [2]. The
role of the microenvironment in tumor cell fate regulation has
been reported as early as Paget's “seed and soil hypothesis” [3].
This hypothesis was expanded upon by Fidler [2], who suggested
that tumor cells (i.e. seed) extravagate into circulation, survive,
and establish in a distant site (i.e. soil), and their fate (death,
dormancy, or growth) is directly inﬂuenced by the microenviron-
ment of the distant site. The “seed and soil” hypothesis has been
used to describe many different tumor-related diseases, including
prostate cancer, which has a particular predilection for metastasis
to bone which also houses the hematopoietic stem cell (HSC).
Toward this end, 80% of advanced prostate cancer cases exhibit
distant site metastasis in bone accompanied by a median survival
of approximately 40 months [4]. Here, we discuss insights into the
role of the HSC niche in prostate cancer (PCa) bone metastasis.GmbH. This is an open access art
.2. Homing of DTCs to the HSC niche
The HSC niche is a complex microenvironment comprised of
many cell types, including endothelial cells, adipocytes, osteo-
clasts, osteomacs, and cells of osteoblastic lineage [5]. A healthy
HSC niche provides homing signals to healthy HSCs in order to
promote their normal function [6]. Shiozawa et al. [7] demon-
strated that increasing the number of HSC niches promoted in-
creased number of bone marrow DTCs, which indicated these
same homing signals can be exploited in PCa metastasis. Two
important mediators of the HSC microenvironment are the che-
mo-attractant stromal derived factor-1 (SDF-1 or CXCL12) and the
cell attachment factor (Annexin2 or ANXA2). CXCL12 regulates
HSC homing to the bone marrow as well as mobilization into cir-
culation, while ANXA2 is likely involved in HSC binding to the
osteoblastic niche, and may act as an anchor of CXCL12 and aid in
localization to the niche [8]. Recently, it was shown that bone
marrow stromal cells expressing enhanced levels of CXCL12 and
ANXA2 increases recruitment of PCa cells into the bone marrow,
promotes proliferation of PCa cells, and protects PCa cells from
chemotherapy induced apoptosis [9]. These data suggest that DTCs
may home to the HSC niche using similar mechanisms to the HSCs
themselves in the regulation of cell fate.3. DTC dormancy in the HSC niche
The concept of a dormancy supportive/permissive micro-
environment in the bone marrow is an increasingly important and
complex area of investigation in clinical oncology due to theicle under the CC BY-NC-ND license
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mitotic cells [10]. There are many mechanisms by which DTC
mitotic cycling is affected including regulation of the immune
system, angiogenesis/nutrients, tumor extracellular matrix, and
hormones [11]. In the HSC niche, cancer cells are subject to HSC
quiescent signaling mechanisms, and a number of possible con-
tributing chemokines have been identiﬁed [7,12]. DTC dormancy
can be achieved through lack of activating signals (e.g. Wnt, Notch)
or directly due to inhibitory signals (BMPs) [13]. Aguirre-Ghiso
et al. [14] demonstrated that the balance between p38 and ERK,
both mitogen activated kinases (MAPKs), affect DTC mitotic state.
When ERK is elevated compared to p38, proliferation is favored;
conversely, elevation of p38 compared to ERK favors quiescence.
The balance of ERK and p38 in vivo is further regulated by other
ligands: down-regulation of urokinase receptor (uPAR) results in
an ERKLow/p38High signaling ratio, inducing proliferative behavior
in squamous carcinoma cells (HEp3) [15]. BMP7 has also been
demonstrated to induce dormancy in PCa cells through the p38
MAPK pathway [16].
Other HSC-mediated factors, such as low oxygen [17], angio-
genic [18], or additional secreted factors can also control dor-
mancy. Shiozawa et al. [19] reported that growth arrest speciﬁc-6
(GAS6), a ligand of TYRO3, AXL, and MER tyrosine kinase receptors
produced by osteoblasts in the HSC niche, supported PCa cell
dormancy with increased survival and additionally prevented
proliferation. Additionally, angiogenic simulators c-myc, vascular
endothelial factor (VEGF), and ﬁbroblast growth factor 2(FGF2)
may be involved in exit of DTCs from dormancy [20,21]. Under-
standing the mechanisms of DTC dormancy may lead to better
targeted therapies for metastatic disease.4. The role of DTCs in niche formation
Following localization to the bone marrow, DTCs or their pro-
geny can have osteoblastic or osteolytic effects, or both activities
[22]. Osteoblastic lesions stimulate osteoblast formation and pro-
mote bone formation, albeit poorly woven bone [4]. Osteolytic
lesions stimulate osteoclastic activity, which results in bone loss.
In the instance of PCa, the impact of DTCs have been observed to
be both osteoblastic and osteolytic in nature [23]. Joseph et al. [24]
demonstrated that hematopoietic progenitor cells (HPCs) from
mice inoculated with LNCaP-derived C4-2B induced osteoblastic
differentiation of bone marrow stromal cells in co-culture through
production of BMP-2. Conversely, these authors reported HSCs
from mice inoculated with the PCa cell line, PC3, induced osteo-
clastic activity resulting in predominantly osteolytic lesions
through an IL-6 mediated signaling pathway. Applications of this
research include using HSC/HPC targeted therapy to limit the ef-
fects of bone metastasis. However, more research is needed to
understand the precise mechanisms through which metastatic
lesions may direct niche formation.5. Erythropoietin and the HSC niche
Many molecules produced both locally and systemically, in-
cluding erythropoietin (Epo) and adrenergic catecholamines, also
appear to affect HSC niche and metastatic lesions in the bone
marrow. EPO is a hematopoietic hormone produced pre-
dominantly in the kidneys in response to hypoxia. EPO functions
through binding to a preformed homodimer transmembrane re-
ceptor (Epo-R). Interestingly, Epo-R is expressed in both
hematopoietic and non-hematopoietic tissues, suggesting that the
role of Epo may be more widespread beyond hematopoiesis [25].
The mRNA expression of Epo-R has been reported in tissues of thebrain, testes, placenta, heart, lungs, bone marrow, spleen, and even
tumor cells [26–28].
In cancer, Epo has both direct and indirect actions on DTCs in
the HSC niche. First, Epo may directly act on tumor cells located
within the bone marrow. Some studies provide evidence that Epo/
Epo-R axis activation leads to tumor cell proliferation; while other
studies demonstrate Epo/Epo-R activation did not support tumor
cell growth speciﬁcally [29]. Interestingly, Shiozawa et al. [30]
demonstrated that Epo did not stimulate PCa tumor cell (using PCa
cell lines) proliferation in vitro, or enhance metastasis in vivo;
however, these authors did demonstrate an increased tumor cell
resistance to apoptosis resulting in PCa cell survival. Similarly,
Todaro et al. [31] reported that Epo stimulation increased re-
sistance of breast cancer stem-like cells (BCSC) isolated from pa-
tient tumors to chemotherapeutics, doxorubicin and 5-FU, in vitro
and in a subcutaneous mouse model. Further, they reported sti-
mulation with Epo upregulated known survival pathway media-
tors—Akt, Erk, and Bcl-xL—which may explain the mechanism by
which BCSC cells achieved protection from chemotherapy [31].
These remain among the possible mechanisms that affect cancer
therapy and may impact patient survival, through resistance of
DTCs within the bone marrow to current chemotherapeutics [32].
There is also evidence that Epo increases niche formation,
which may indirectly affect cancer cells or DTCs residing within
the bone marrow niche [33,34]. It was previously reported that
blood loss stimulates HSCs and may activate osteoprogenitor cells
[35]. Further, Jung et al. [33] demonstrated that HSCs isolated from
animals subjected to an acute bleed, showed increased capacity to
induce osteoblastic differentiation, due to increased HSC-derived
BMP-2 and BMP-6. Later, Shiozawa et al. [36] reported blood loss
induced Epo production, causing BMP production in HSCs through
a Jak/Stat signaling mechanism. In addition Epo regulates the bone
microenvironment through direct action on mesenchymal cells,
inducing osteoblast differentiation. Thus demonstrating that Epo
can regulate bone metabolism through induction of osteoblast
differentiation or production of BMPs by HSCs [34,36]. Further
investigation showed increased angiogenesis as well as elevated
numbers of red blood cells in the peripheral blood, and me-
senchymal cells and hematopoietic stem cells in the bone marrow
[34]. Taken together, understanding the role of Epo on the niche,
within which DTCs reside may aid in the development of effective
treatment modalities for cancer patients.
Together these data demonstrate interconnectivity of hemato-
poiesis and tumor metastasis. On one side the HSC niche is tar-
geted by circulating tumor cells to facilitate the establishment of
DTCs in marrow. Once there, DTCs are likely to undergo one of
three fate decisions: apoptosis, dormancy or proliferation. Each of
these fate choices are likely regulated by the niche by soluble and
non-soluble factors. The niche, as an integrator of systemic de-
mands for hematopoiesis, also is likely able to regulate DTC fate
when occupied by these molecular parasites. Yet how this occurs,
remains poorly understood. Similarly, progeny of DTCs are able to
produce osteoblastic, osteolytic lesions or mixed. How this occurs
is also not well understood and how the niche participates or
regulates these activities is an active area of investigation (Fig. 1).6. 10 outstanding questions in the ﬁeld1. What is dormancy – is it a lack of proliferation or does pro-
liferation and cell death balance out for a zero gain of cell
numbers?
2. Does signaling remain the same if metastatic tumor cells re-
place HSCs in the niche?
3. What mechanisms govern dormancy and disease recurrence in
Fig. 1. Model of Dormancy and Activation of PCa metastasis within the bone marrow niche. The bone marrow niche is a functionally dynamic component in the activity of
metastatic cancer cells. PCa cells express receptors for CXCL12, Annexin2, and Gas6, which instigate dormancy and reduce mitotic activity. Conversely, dormant DTCs can be
reactivated through external signals, such as Epo. PCa¼Prostate Cancer; OBs¼osteoblasts.
A.M. Decker et al. / Journal of Bone Oncology 5 (2016) 117–120 119the bone marrow?
4. Is dormancy or tumor reactivation a stochastic or a cell au-
tonomous event.
5. Is dormancy and the exit from regulated by multiple signals
and how are they integrated?
6. What happens to DTCs that do not engage the HSC niche? Are
these cells more likely to undergo apoptosis, awakening, or do
they simply fail to survive?
7. Relapse following curative therapy is often the result of a few
DTC clones which become reactivated. How is this
coordinated?
8. Why does EPO/EPO-R axis stimulation differ among tumor cell
type populations?
9. How can the positive clinical effects of EPO be maintained,
while eliminating the harmful effects of EPO on tumor cells?
10. What is the mechanism by which Epo stimulates DTC re-
activation in the niche?Acknowledgments
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